Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ficlatuzumab, rilotumumab | 0.81 |
| trials ClinicalTrials.gov | 17 Parkinson's trials, 1 stopped | 0.95 |
| literature PubMed | 18 Parkinson's papers of 13,319 | 0.61 |
| pathways Reactome | 18 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 4469
Sealed predictions
- HGF in dopamine neurons, braak+0.64 (p 0.063) → +0.55 (p 0.125)receipt 4476
Swarm cases
receipt 4476: HGF in dopamine neurons, braak
- power
- full sample +0.56 (p 0.016, n 18), 95% CI +0.13 to +0.81. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.51 (p 0.031, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.51 (p 0.031, n 18). not the mix.
- skeptic
- leave-one-out range +0.50 to +0.76, sign flips 0; without severely affected donors +0.56 (p 0.016, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for HGF in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts